Comprehensive analysis of mitochondrial solute carrier family 25 (SLC25) identifies member 19 (SLC25A19) as a regulatory factor in hepatocellular carcinoma

作者：Xueke Gao, Yangtao Xu, Xinyao Hu, Jiayu Chen, Daoming Zhang, Ximing Xu · 发表于：Gene · 年份：2025 · DOI：10.1016/j.gene.2025.149299 · 被引用次数：4 · 研究领域：Mitochondrial Function and Pathology、Ferroptosis and cancer prognosis、GDF15 and Related Biomarkers

• SLC25-based subtypes stratify HCC prognosis. • Triple-gene (SLC25A19/49/51) model predicts HCC outcome. • Single-cell sequencing identifies SLC25A19 as independent HCC prognostic marker. • SLC25A19 drives HCC growth via Wnt pathway. The mitochondrial solute carrier family 25 (SLC25) is known to play a pivotal role in oncogenesis, yet its specific involvement in hepatocellular carcinoma (HCC) remains poorly elucidated. In this study, we performed a clustering analysis of HCC patients in the Cancer Genome Atlas database based on the expression levels of SLC25 members, and conducted clinical feature analysis for each patient within the clusters. Subsequently, we developed a prognostic model using a Lasso regression approach with SLC25A19, SLC25A49, and SLC25A51 as features, and generated a risk score for each HCC patient. We then identified SLC25A19 as a potential prognostic marker for HCC through single-cell analysis, and validated this finding using in vitro and in vivo experiments. Our results revealed significant differences in the expression of most SLC25 family members in HCC patients, enabling the stratification of patients into three clusters, with those in cluster 1 exhibiting the most favorable prognosis and showing a correlation with enhanced immune infiltration. The risk scores derived from the features SLC25A19, SLC25A49, and SLC25A51 effectively predicted the prognosis of HCC patients, with area under the curve (AUC) values exceeding 0.7 in the test group. Single...